Veru (NASDAQ:VERU – Free Report) had its price target lifted by HC Wainwright from $2.00 to $3.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock.
VERU has been the subject of several other research reports. Raymond James assumed coverage on shares of Veru in a report on Thursday, March 28th. They issued an outperform rating and a $3.00 price target for the company. Oppenheimer reissued an outperform rating and issued a $5.00 target price (down from $7.00) on shares of Veru in a research note on Monday, April 15th.
View Our Latest Analysis on VERU
Veru Stock Down 12.3 %
Veru (NASDAQ:VERU – Get Free Report) last announced its quarterly earnings results on Monday, April 1st. The company reported ($0.09) EPS for the quarter. Veru had a negative net margin of 405.04% and a negative return on equity of 257.92%. The company had revenue of $2.14 million during the quarter. Analysts expect that Veru will post -0.26 EPS for the current fiscal year.
Institutional Investors Weigh In On Veru
Institutional investors have recently added to or reduced their stakes in the stock. Choreo LLC bought a new stake in shares of Veru in the first quarter valued at about $64,000. Rosalind Advisors Inc. lifted its stake in Veru by 12.5% in the 1st quarter. Rosalind Advisors Inc. now owns 4,500,000 shares of the company’s stock valued at $3,150,000 after acquiring an additional 500,000 shares in the last quarter. 180 Wealth Advisors LLC bought a new position in shares of Veru during the 1st quarter worth approximately $120,000. Perceptive Advisors LLC boosted its holdings in Veru by 412.4% during the fourth quarter. Perceptive Advisors LLC now owns 5,584,699 shares of the company’s stock worth $4,021,000 after purchasing an additional 4,494,821 shares during the last quarter. Finally, Octagon Capital Advisors LP bought a new position in Veru in the fourth quarter valued at $2,736,000. 47.16% of the stock is owned by institutional investors.
About Veru
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Read More
- Five stocks we like better than Veru
- What is a buyback in stocks? A comprehensive guide for investors
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Generac Powers Ahead on the Electrification Mega-Trend
- Most active stocks: Dollar volume vs share volume
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.